Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systematic screening of potential beta-cell imaging agents.

Ian R Sweet1, Daniel L Cook, Ake Lernmark

  • 1Departments of Medicine, University of Washington, Seattle, WA 98195, USA. isweet@u.washington.edu

Biochemical and Biophysical Research Communications
|January 31, 2004
PubMed
Summary

Developing specific imaging agents for positron emission tomography (PET) is crucial for monitoring beta-cell loss in diabetes. Current compounds show insufficient specificity for accurate beta-cell mass quantification.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk estimation and dynamic prediction using discrete-time joint models for longitudinal and multistate data with interval and state censoring.

Biostatistics (Oxford, England)·2026
Same author

Retinol, Carotenoid, and Tocopherol Intake and Status, and the Risk of Islet Autoimmunity and Type 1 Diabetes: The Environmental Determinants of Diabetes in the Young Study.

Diabetes/metabolism research and reviews·2026
Same author

Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile.

Diabetes care·2026
Same author

Heterogeneity between insulin and proinsulin in the potency for insulin autoantibodies in newly diagnosed type 1 diabetes children.

Clinical and experimental immunology·2026
Same author

Corrigendum to: Autoreactive T cell receptors with shared germline-like α chains in type 1 diabetes.

JCI insight·2026
Same author

Polymorphisms in intron 1 of HLA-DRA differentially associate with type 1 diabetes and celiac disease and implicate involvement of complement system genes C4A and C4B.

eLife·2026

Area of Science:

  • Endocrinology and Metabolism
  • Medical Imaging
  • Pharmacology

Background:

  • Diabetes mellitus is characterized by beta-cell loss, necessitating methods for clinical monitoring.
  • Positron emission tomography (PET) offers potential for quantifying beta-cell mass, but requires highly specific imaging agents.
  • The pancreas has a high ratio of non-beta-cell to beta-cell tissue, posing a challenge for imaging specificity.

Purpose of the Study:

  • To develop and validate a screening assay for identifying beta-cell-specific compounds.
  • To evaluate candidate molecules for their potential as PET imaging agents for beta-cell mass.

Main Methods:

  • A screening assay was established based on the relative accumulation and retention of candidate molecules by islet, INS-1 (beta-cell line), and PANC-1 (exocrine cell line) cells.

Related Experiment Videos

  • Candidate molecules including glibenclamide, tolbutamide, serotonin, L-DOPA, dopamine, nicotinamide, fluorodeoxyglucose, and fluorodithizone were tested.
  • In vitro specificity was assessed, followed by in vivo biodistribution studies of promising compounds in rats.

    • Main Results:

    • Glibenclamide and fluorodithizone demonstrated the highest specificity among the tested compounds.
    • However, the specificity ratios for glibenclamide and fluorodithizone were insufficient for robust PET imaging of beta-cell mass.
    • In vivo biodistribution studies confirmed that glibenclamide and fluorodithizone were not specifically localized to the pancreas.

    Conclusions:

    • The developed screening assay can identify beta-cell-specific compounds.
    • Current candidate molecules, including glibenclamide and fluorodithizone, lack the required specificity for PET imaging of beta-cell mass.
    • Further research is needed to discover or develop novel imaging agents with improved beta-cell specificity.